At Mylan, delivering better health for a better America isn’t our job. It's our mission.


We believe everyone deserves the opportunity to live a healthy life, including you. That’s why, for more than 55 years, Mylan has focused on providing access to high quality medicine and setting new standards in healthcare.

Better Health for a Better America
See Mylan's impact in your state  

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine.

We market more than 7,500 products worldwide, including prescription generic and brand-name medicines as well as consumer health products such as over-the-counter remedies – and, increasingly, we offer services a­nd patient-support programs to help promote better health.

The company was founded in the U.S. in 1961 by two Army buddies who wanted to make medicine accessible to people living in rural West Virginia. From those humble beginnings, Mylan grew, providing patients in more than 165 countries and territories last year with 68 billion doses of medicine.

Making it happen each and every day are the members of our more than 35,000-strong global workforce. They do what they love – harnessing the wonders of science, the benefits of scale, the power and reach of digital technologies, the fruit of persistence and the gift of compassion – so that you and those you care about can do what you love.

Learn more in this interactive portal about how we are bringing better health to your corner of the world.

Innovation is occurring around the clock in more than a dozen R&D sites around the world.
>6,000
people working in Quality globally
~3,000
Scientific and Regulatory Affairs experts globally
165
We serve patients in more than 165 countries and territories.
7,500
products marketed worldwide
50
manufacturing sites
35,000+
global workforce

Committed to Access

We believe access to healthcare should be a right, not a privilege.

That makes our mission very personal. After all, everyone we’re trying to reach is somebody’s friend, neighbor or family member, including our own. So although you may not know Mylan by name, rest assured we’re fighting every day to make sure the medicines people need are accessible. In fact, chances are, you or someone you love already has our quality products in your medicine cabinet.


Learn how Mylan is your champion.

Substantial Savings

Mylan understands that people are concerned about the price of prescription drugs. So are we. We never want price to prevent patients from getting the medicine they need. That’s why we continue to leverage our heritage as a generics manufacturer to help drive down costs. In 2016 alone, generic drugs reduced U.S. prescription drug costs by $253 billion - $25 billion of which came from Mylan drug products. After all, making affordable medicine accessible isn’t our job. It’s our mission.

In 2016, generics filled 3.9 billion prescriptions in the U.S., or 89% of those dispensed. Mylan’s generics filled 10% of them, or390 million prescriptions.
In 2016, Mylan’s generics saved the U.S. nearly$25 billion.
U.S. Portfolio

Medicines You Need

Mylan is a leader today in offering medications that address a range of health concerns around the world, from the common cold to serious diseases like cancer, autoimmune disorders, diabetes and Alzheimer’s. We’re also working to introduce generic and biosimilar versions of some of the world’s most complex and costly medicines, including insulins, biologics and respiratory therapies. Our singular focus is on delivering better health in the part of the world that matters most to you and your family.

The average selling price in 2016 of Mylan’s medicines in the U.S., branded and generic, was just
25¢ per dose.

1 out of every 13
prescriptions dispensed in the U.S., brand name or generic, is filled with a Mylan product.

In the U.S., Mylan offers more than
635 medicines.

Mylan product filled more prescriptions in 2016 than AstraZeneca, GSK, Johnson & Johnson, Lilly, Merck, Pfizer and Sanofi COMBINED.

Mylan is a leader in the fight against many of our nation’s most prevalent diseases.

From Our Medicine Cabinet to Yours

Medicines can help people only if they’re available when and where they’re needed. Mylan does everything possible to make sure our life-changing medicines are always in stock at pharmacies, medical facilities and other places where patients – and their doctors, nurses or caregivers – expect them to be. We think peace of mind is great medicine, too.

>20BMylan produces more than 20 billion doses of medicine in the U.S. each year.
~80%of Mylan’s products sold in America are manufactured in America.
~$3BMylan has invested ~$3B in capital expenditures globally, which includes a significant investment in manufacturing, over the last decade.

Mylan’s manufacturing operations are largely vertically integrated – meaning we produce active pharmaceutical ingredients and finished medicines, which gives us substantial control over the cost and quality of our products.

Watch how Mylan tablets and capsules are made.

Healthcare You Deserve

Going Beyond Medicine

Because there’s more to delivering better health than offering quality medicine, Mylan thinks in terms of fighting disease. Doing so reveals opportunities to provide patients with prescription generic and branded medicines and consumer health products such as over-the-counter remedies – and to wrap them in services focused on wellness, prevention and adherence, such as reminders to refill prescriptions. It’s Mylan’s way of putting the care back in healthcare.


Mylan’s clear vision for Women’s Healthcare, for instance, means providing access to vital medications throughout every woman’s lifetime – such as those that treat cardiovascular diseases, cancer and diabetes.

And for the more than 1.5 million people diagnosed with cancer each year in the U.S., Mylan is committed to helping them. We’re one of the largest suppliers of cancer medicines by volume in the nation.

>1.5M
people diagnosed with cancer each year in the U.S.

Mylan is one of the largest suppliers of cancer medicines by volume in the U.S.

>29M
Diabetes affects >29M people in the U.S.

Mylan is a leading producer of oral diabetes medicines.

16.5M
people receive ARV treatments in developing countries.

>40% of all patients globally being treated for HIV/AIDS depend on a Mylan product.

Innovating to Meet Unmet Needs

At Mylan, we have a long tradition of innovation.

In fact, we have invested approximately $5 billion in research and development globally over the last decade. And whether we’re developing more affordable versions of insulins, biologics or respiratory therapies, better health for a better America is our goal.


Watch The Mylan Story.

Investing for Now and the Future

We know the more medicines we make, the more patients we can reach. That’s why Mylan invests significantly in scientific research.

Mylan has:

2 global R&D centers, including one in West Virginia
12 technology-focused R&D sites, including one in Texas and one in Vermont
>4,200 active patents
>1,800 new product submissions pending approval around the world
~3,000 Scientific and Regulatory Affairs experts globally
Over the last several years, Mylan is among the top companies receiving FDA approvals for generic drug applications. In fact, we have obtained more than 130 approvals in the last three years alone.
Challenging the Status Quo

Mylan takes on challenges no one else will. We focus on developing innovative, cost-effective and patient-friendly treatments for diseases like cancer, diabetes, HIV/AIDS and more. For example, lack of refrigeration once meant lack of access to antiretroviral (ARV) medicines for millions of people living with HIV/AIDS in developing countries. That’s because some ARVs must be kept cool. Our scientists responded by making heat-stable formulations. And Mylan’s innovations go way beyond medicines. Our services and patient-support programs address a wide range of health issues.


Watch how Mylan helps HIV/AIDS patients in the developing world.

Delivering Medicine the Way Patients Need It
The way people take our products is as diverse as the patient populations we serve. From tablets and capsules, injectables and ointments to inhalers and transdermals – Mylan provides patients the medicine they need, the way they need it.

Manufacturing Capacity

80B
oral solid doses (e.g., bilayer tablets, modified- and immediate-release tablets and capsules and orally disintegrating tablets)
500M
injectables (e.g., pre-filled syringes, bags and lyophilized products)
1.5B
complex products (e.g., transdermals, dermals, topicals, respiratory, oral films and other specialty items)
Driving Access to Advanced Treatments

Mylan has always been known for our expertise in developing “difficult-to-develop” medicines. In fact, we relish opportunities that others shy away from. Many of these drugs are used to treat diseases like cancer, autoimmune disorders, chronic obstructive pulmonary disease (COPD) and diabetes.


Read more about:

Mylan and biosimilars

Mylan and women’s health

Mylan and oncology

8 in 10
of the 23.5M Americans who suffer from autoimmune disorders are women.
1 in 3
In her lifetime, 1 in 3 women will be diagnosed with cancer in the U.S.

Mylan has 16 biosimilar and insulin analog products on the market around the world or in development.

They include 8 of the top 10 biologics in areas of oncology, immunology, endocrinology and ophthalmology.

Your Voice is Our Voice

One of the most powerful ways to serve patients in need is by speaking out on their behalf.


Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health. To this process we bring an open mind, deep experience, and meaningful solutions to address pressing public and health policy challenges.

Making Medicine More Accessible

Nothing frustrates us more than knowing that medicines are available, but people can’t access them. Mylan works to identify why and takes action. Mylan has a decades-long track record of successfully fighting to break down such barriers, particularly by helping to make more-affordable generic versions of brand name drugs widely available – expertise we’re now bringing to biologics, insulins and other complex medicines.


To help increase access, Mylan:

  • Helped found the U.S. generic industry’s first trade association
  • Helped give rise to groundbreaking Hatch-Waxman legislation, which created the modern generics industry in the U.S. in 1984
  • Helped shape the Medicare Modernization Act, enacted in 2003
  • Through the 2012 Food and Drug Administration Safety and Innovation Act and Generic Drug User Fee Act, led the way for a level playing field to ensure one quality standard for all medicines sold in the U.S.

A circle chart showing 19 percent
1984

In 1984, generic drugs made up only 19% of prescriptions dispensed in the U.S.

A circle chart showing 89 percent
2016

Last year, they made up 89% of prescriptions dispensed.


Generics make up 89% of prescriptions dispensed in the U.S.,

yet represent only 26% of total drug spending.

Biosimilars

The introduction of just 11 biosimilars in the U.S. could save the nation’s healthcare system $250 billion over 10 years.

Mylan has 16 biosimilar and insulin analog products on the market around the world or in development. They include eight of the world’s top 10 biologics focused on the areas of oncology, immunology, endocrinology and ophthalmology.

Addressing an Important Need in Schools

Epinephrine is the only first-line treatment for anaphylaxis, a potentially life-threatening allergic reaction. Several years ago, however, we realized that a child experiencing anaphylaxis in school may not have access to epinephrine auto-injectors – even if they were on hand – if the prescription was not in that child’s name or if school nurses or other individuals were not authorized to use them.

Mylan saw this as something that needed to change and took action. We recognized that epinephrine auto-injectors needed to be just as accessible as defibrillators in public spaces. We advocated for legislation that would permit “undesignated” epinephrine auto-injectors in schools – meaning a prescription could be in a school’s name rather than in a child’s name and any individual experiencing an anaphylactic emergency would have access to the epinephrine auto-injectors. Today, 48 states have adopted such laws, and Mylan has donated nearly 1 million epinephrine auto-injectors to more than 73,000 schools around the country.

Stemming the Tide of HIV/AIDS

Helping those in need is a gift that benefits everyone.

A great example is Mylan’s work to stem the tide of HIV/AIDS. Not only are we the world’s largest producer of HIV/AIDS drugs, we also are vocal supporters of policies designed to treat the disease swiftly or, better yet, prevent it altogether. Our work is reaching people in some of the most underserved areas of the world, while helping protect our nation’s borders and make the world safer from infectious-disease threats.

>40%

of all people being treated for HIV/AIDS depend on a Mylan HIV/AIDS medicine.

>50%

of Mylan’s active pharmaceutical ingredient manufacturing capacity is devoted to HIV/AIDS medicines.

Doing Good

At Mylan, making the world a better place is in our DNA. Whether we are providing good jobs for our U.S. workforce of approximately 7,000, donating medicines to clinics in the U.S., or providing financial support for a little league baseball team in one of our local communities, Mylan has always worked hard to strengthen local communities.

U.S. workforce of

~7,000

~2,500

science & technology jobs in the U.S.

Supporting the U.S. Economy

High Quality Jobs, High Quality Employer

Mylan’s most valuable asset is our people. And our jobs aren’t just any jobs. Mylan provides thousands of roles in manufacturing, science and technology in the U.S. alone. Workforce diversity is another one of our strengths, and we encourage employees to raise their hand for opportunities and challenge the status quo.

35%

of Mylan’s U.S. workforce works in a scientific or technology role.

22%

of Mylan’s global workforce took on new roles in 2016.

60%

of Mylan’s U.S. workforce is directly responsible for production of medicines.

46%

of Mylan’s global workforce are millennials.

Partnering With the Community

Mylan understands that it takes a village to sustain a village. And because we are in the business of making high quality medicine, Mylan looks for and responds to opportunities to donate medicines we produce to those who need it most.


Since 2007

2.2B

doses of medicine donated throughout the world

114M+

doses of medicine donated to patients in the U.S.

Philanthropic Impact

Mylan Cares

When Mylan was founded in a rural community of West Virginia in 1961, giving back to the communities where we operate became a core value and common practice. Over the years, we’ve supported countless local and national organizations and causes. Organizations we’ve supported recently include: American Cancer Society, American Heart Association, American Red Cross, Habitat for Humanity, Hugh O’Brien Youth Leadership, and National MS Society, to name a few.

Awareness, Preparedness & Access to Treatment for Anaphylaxis

Mylan’s commitment to expanding access to medicine extends beyond just offering products. Take potentially life-threatening allergic reactions, or anaphylaxis. These reactions can occur quickly and without warning. An estimated one in 13 children is affected by food allergies, a common trigger for anaphylaxis, and as many as one in 20 adults in the U.S. are at risk. Many don’t even know it. Approximately 25% of life-threatening allergic reactions reported at schools, for example, have occurred in those with no previous diagnosis of a food allergy. Moreover, the rate of reported severe allergic reactions to food alone has increased by nearly five times over the past decade.

To help manage life-threatening situations, Mylan has worked hard to get the word out about the importance of avoiding allergic triggers, being prepared in case anaphylaxis occurs and ensuring that effective treatment is at hand when needed.

Mylan is committed to helping ensure that every patient who needs an epinephrine auto-injector is able to access one. Learn more about what we have done to improve access through our resources here. This includes information about our authorized generic for EpiPen® (epinephrine injection, USP) Auto-Injector, patient savings cards and patient assistance program.

Up to 43 million people may have allergic sensitivities that put them at risk.

Every 6 minutes food-related anaphylaxis sends someone to the emergency room.

1 in 3

Epinephrine is the only first-line treatment for anaphylaxis.

Yet according to a recent study, 1 in 3 patients prescribed epinephrine failed to carry their medication during a reported anaphylactic event, demonstrating the continued need for awareness and education.

EpiPen4Schools®

In 2012, Mylan took the fight against anaphylaxis to schools throughout the country when we launched EpiPen4Schools. The program provides four FREE epinephrine auto-injectors to qualifying* U.S. public and private kindergarten, elementary, middle and high schools, along with additional training and educational resources.


900K

Over the past five years, more than 900,000 free epinephrine auto-injectors have been provided to more than 73,000 schools nationwide, approximately 54% of schools


Since the program began in 2012, epinephrine auto-injectors provided through the EpiPen4Schools program have been used more than 2,000 times across nearly every state to treat an anaphylactic reaction in the school setting. This reinforces the need for increased access to treatment in schools.

 Learn how schools can enroll in the program at EpiPen4Schools.com.

A Deeper Look

The EpiPen4Schools program is making a difference according to data from a survey of program participants during the 2013-2014 and 2014-2015 school years. Results showed that anaphylaxis occurred across all grade levels and in individuals with or without known risk factors, underscoring the need for school preparedness in both managing anaphylaxis and stocking epinephrine auto-injectors through programs like Mylan’s.

Survey results highlights:

  • In anaphylactic events when an epinephrine auto-injector was used, nearly half were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program.
  • A substantial proportion of anaphylactic events occurred in students with no known history of severe allergies.
  • Higher anaphylactic event rates occur among high school students compared with younger grade levels.

Advancing Public Policy

Mylan’s EpiPen4Schools program would not have been possible without various legislative advancements made in recent years. As part of our ongoing commitment to increase access to treatment, we partnered with advocacy groups and public policy leaders to back legislation that would permit undesignated epinephrine auto-injectors, not specific to any brand or student, in schools and other public places. When starting these efforts, we knew that it would not be easy and would take time as this had not been done before. However, we have remained committed to supporting this important community, and significant progress has been made.


8 to 48

In 2010, only eight states had legislation that allowed undesignated, or “stock,” epinephrine in schools. Today, 48 states have enacted laws or policies allowing it.


We’re not stopping there. We’ve also been working to make undesignated epinephrine auto-injectors available in other public places, such as restaurants, colleges and universities. As a result, stock epinephrine in public places now is permitted in 31 states.

A recent survey conducted by the U.S. Centers for Disease Control found that in nearly half of peanut and tree nut allergic reactions in restaurants or other food-service establishments, the food allergic customers had alerted the restaurant to their severe allergy in advance.

Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-395-3376.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.



Back to top
Learn more at Mylan.com

Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.